PeptideTrace
Research CompoundNeuropeptide (Sleep-Related, Unregulated)

DSIP

Delta Sleep-Inducing Peptide

C

Evidence Grade C — Moderate human evidence. 346 published studies, 88 human. 0 registered clinical trials.

346 studiesUSEUCA

Overview

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring peptide discovered in 1977 from rabbit brain during sleep experiments. Despite its name, its connection to sleep remains unproven — after nearly five decades of research, no specific receptor has been identified and multiple independent laboratories have failed to consistently replicate the original sleep-promoting claims.

Research Activity

346studies
Human 88
Animal 236
In-vitro 26
Reviews 10

346 published studies: 88 human, 236 animal, 26 in-vitro, 10 reviews

Regulatory Status

US
Not approved by FDA(FDA)
EU
Not authorised by EMA(EMA)
CA
Not approved by Health Canada(Health Canada)

Legal Status

USNot applicable (not approved)
EUNot applicable (not authorised)
CANot applicable (not approved)

Summary

DSIP has no marketing authorisation. Small clinical studies from the 1980s investigated sleep and withdrawal symptom applications, but these trials had significant methodological limitations including small sample sizes and inadequate controls. No modern clinical trials meeting current standards have been conducted.

The compound's discovery preceded the identification of its mechanism — and after nearly five decades, no specific receptor has been definitively established. This mechanistic uncertainty distinguishes DSIP from most other research compounds. Products available through unregulated channels lack pharmaceutical quality assurance.

Mechanism of Action

Research has not identified a specific receptor or defined mechanism for DSIP. Proposed mechanisms include interactions with multiple neurotransmitter systems including NMDA receptors, opioid systems, and GABAergic signalling. The inability to identify a clear receptor target or consistent mechanism is a fundamental limitation of this compound's evidence base.

Research Summary

Research suggests the inability to identify a receptor, a gene, or a reproducible sleep-inducing mechanism after 40+ years is a fundamental scientific concern. All clinical studies are from the 1980s with small sample sizes and outdated methodology. No modern randomised controlled trials exist. A paradox also remains unexplained: DSIP levels in the body actually decrease during the sleep states it was originally claimed to promote. The compound's biological activity, if any, may be unrelated to sleep. Products from unregulated sources lack pharmaceutical quality assurance.

Clinical Trials

No trials registered on ClinicalTrials.gov for this compound.

The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.